Autophagy as a target for cancer therapy: New developments

Jennifer S. Carew, Kevin R. Kelly, Steffan T. Nawrocki

Research output: Contribution to journalArticle

105 Citations (Scopus)

Abstract

Autophagy is an evolutionarily conserved lysosomal degradation pathway that eliminates cytosolic proteins, macromolecules, organelles, and protein aggregates. Activation of autophagy may function as a tumor suppressor by degrading defective organelles and other cellular components. However, this pathway may also be exploited by cancer cells to generate nutrients and energy during periods of starvation, hypoxia, and stress induced by chemotherapy. Therefore, induction of autophagy has emerged as a drug resistance mechanism that promotes cancer cell survival via self-digestion. Numerous preclinical studies have demonstrated that inhibition of autophagy enhances the activity of a broad array of anticancer agents. Thus, targeting autophagy may be a global anticancer strategy that may improve the efficacy of many standard of care agents. These results have led to multiple clinical trials to evaluate autophagy inhibition in combination with conventional chemotherapy. In this review, we summarize the anticancer agents that have been reported to modulate autophagy and discuss new developments in autophagy inhibition as an anticancer strategy.

Original languageEnglish (US)
Pages (from-to)357-365
Number of pages9
JournalCancer Management and Research
Volume4
Issue number1
DOIs
StatePublished - Oct 10 2012

Fingerprint

Autophagy
Neoplasms
Therapeutics
Organelles
Antineoplastic Agents
Drug Therapy
Standard of Care
Starvation
Drug Resistance
Digestion
Cell Survival
Clinical Trials
Food

Keywords

  • Apoptosis
  • Autophagy
  • Cancer
  • Chloroquine
  • Lucanthone

ASJC Scopus subject areas

  • Oncology

Cite this

Autophagy as a target for cancer therapy : New developments. / Carew, Jennifer S.; Kelly, Kevin R.; Nawrocki, Steffan T.

In: Cancer Management and Research, Vol. 4, No. 1, 10.10.2012, p. 357-365.

Research output: Contribution to journalArticle

Carew, Jennifer S. ; Kelly, Kevin R. ; Nawrocki, Steffan T. / Autophagy as a target for cancer therapy : New developments. In: Cancer Management and Research. 2012 ; Vol. 4, No. 1. pp. 357-365.
@article{92efb660712e4126ababe700b6270c08,
title = "Autophagy as a target for cancer therapy: New developments",
abstract = "Autophagy is an evolutionarily conserved lysosomal degradation pathway that eliminates cytosolic proteins, macromolecules, organelles, and protein aggregates. Activation of autophagy may function as a tumor suppressor by degrading defective organelles and other cellular components. However, this pathway may also be exploited by cancer cells to generate nutrients and energy during periods of starvation, hypoxia, and stress induced by chemotherapy. Therefore, induction of autophagy has emerged as a drug resistance mechanism that promotes cancer cell survival via self-digestion. Numerous preclinical studies have demonstrated that inhibition of autophagy enhances the activity of a broad array of anticancer agents. Thus, targeting autophagy may be a global anticancer strategy that may improve the efficacy of many standard of care agents. These results have led to multiple clinical trials to evaluate autophagy inhibition in combination with conventional chemotherapy. In this review, we summarize the anticancer agents that have been reported to modulate autophagy and discuss new developments in autophagy inhibition as an anticancer strategy.",
keywords = "Apoptosis, Autophagy, Cancer, Chloroquine, Lucanthone",
author = "Carew, {Jennifer S.} and Kelly, {Kevin R.} and Nawrocki, {Steffan T.}",
year = "2012",
month = "10",
day = "10",
doi = "10.2147/CMAR.S26133",
language = "English (US)",
volume = "4",
pages = "357--365",
journal = "Cancer Management and Research",
issn = "1179-1322",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

TY - JOUR

T1 - Autophagy as a target for cancer therapy

T2 - New developments

AU - Carew, Jennifer S.

AU - Kelly, Kevin R.

AU - Nawrocki, Steffan T.

PY - 2012/10/10

Y1 - 2012/10/10

N2 - Autophagy is an evolutionarily conserved lysosomal degradation pathway that eliminates cytosolic proteins, macromolecules, organelles, and protein aggregates. Activation of autophagy may function as a tumor suppressor by degrading defective organelles and other cellular components. However, this pathway may also be exploited by cancer cells to generate nutrients and energy during periods of starvation, hypoxia, and stress induced by chemotherapy. Therefore, induction of autophagy has emerged as a drug resistance mechanism that promotes cancer cell survival via self-digestion. Numerous preclinical studies have demonstrated that inhibition of autophagy enhances the activity of a broad array of anticancer agents. Thus, targeting autophagy may be a global anticancer strategy that may improve the efficacy of many standard of care agents. These results have led to multiple clinical trials to evaluate autophagy inhibition in combination with conventional chemotherapy. In this review, we summarize the anticancer agents that have been reported to modulate autophagy and discuss new developments in autophagy inhibition as an anticancer strategy.

AB - Autophagy is an evolutionarily conserved lysosomal degradation pathway that eliminates cytosolic proteins, macromolecules, organelles, and protein aggregates. Activation of autophagy may function as a tumor suppressor by degrading defective organelles and other cellular components. However, this pathway may also be exploited by cancer cells to generate nutrients and energy during periods of starvation, hypoxia, and stress induced by chemotherapy. Therefore, induction of autophagy has emerged as a drug resistance mechanism that promotes cancer cell survival via self-digestion. Numerous preclinical studies have demonstrated that inhibition of autophagy enhances the activity of a broad array of anticancer agents. Thus, targeting autophagy may be a global anticancer strategy that may improve the efficacy of many standard of care agents. These results have led to multiple clinical trials to evaluate autophagy inhibition in combination with conventional chemotherapy. In this review, we summarize the anticancer agents that have been reported to modulate autophagy and discuss new developments in autophagy inhibition as an anticancer strategy.

KW - Apoptosis

KW - Autophagy

KW - Cancer

KW - Chloroquine

KW - Lucanthone

UR - http://www.scopus.com/inward/record.url?scp=84867723524&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867723524&partnerID=8YFLogxK

U2 - 10.2147/CMAR.S26133

DO - 10.2147/CMAR.S26133

M3 - Article

C2 - 23091399

AN - SCOPUS:84867723524

VL - 4

SP - 357

EP - 365

JO - Cancer Management and Research

JF - Cancer Management and Research

SN - 1179-1322

IS - 1

ER -